$TWST

Green Paula sold $2.1M of TWST

Green Paula (SVP of Human Resources) sold 26,137 shares of Twist Bioscience Corp (TWST) at an average of $81.67 ($81.62–$82.17, $2.13M total) across 2 trades on 2026-06-15.

Original reporting
SEC EDGAR · Green Paula
Published Jun 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Insider open-market sales can be interpreted as mild bearish sentiment, but without additional disclosures (earnings, guidance, litigation, trials, or deals) the trading signal is typically weak.

02

Market read

A $2.13M insider sale was reported, which may cause short-term sentiment noise but lacks fundamental catalysts in the text.

03

What to watch

The article does not state whether the insider’s remaining holdings are large relative to prior grants, nor does it provide context on total insider activity or option exercises that could offset selling.

Relevance 6/10Novelty 3/10Timing: filed June 17, covering trades executed June 15

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience SVP of Human Resources Green Paula sold about $2.13M of TWST shares via open-market transactions on June 15.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction. While the sale size is notable, insider sales are often non-informational and the article provides no accompanying corporate event, guidance change, or regulatory action.

Market effects

Minimal. Insider selling at a single biotech toolmaker is unlikely to reset sector expectations.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan does not necessarily imply negative information; sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs not captured here.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Green Paula

    SVP of Human Resources who sold TWST shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.